The development of noninvasive and economical method to evaluate the bone quality using the measurement of serum levels of osteocyte-specific-proteins

我们的初步分析表明，骨细胞特异性蛋白之一基质细胞外磷酸糖蛋白（MEPE）的血清水平与骨质疏松性椎体骨折的多样性有关。然而，利用MEPE单克隆抗体对血清中MEPE衍生片段的氨基序列分析显示，mAb还能与MEPE以外的其他蛋白质衍生的未知肽结合。不幸的是，由于这种外源肽的数量少，而且在单抗中本身具有交叉反应性，因此鉴定这种外源肽的难度太大，因此利用单抗抗MEPE的ELISA临床应用尚未建立。然而，我们的体外研究证实了骨细胞特异性蛋白测量的可能重要性，并显示了临床应用血浆浓度测量的下一个目标蛋白。

It is revealed by our preliminary analysis that serum level of matrix extracellular phosphoglycoprotein (MEPE) that is one of osteocyte-specific-proteins is correlated with the multiplicity of osteoporotic vertebral fracture. However, the amino sequence analysis of MEPE derived fragment present in serum using monoclonal antibodies against MEPE revealed that mAb also bind with the unknown peptide derived from some protein other than MEPE. Identification of this foreign peptide is unfortunately too difficult due to its small amount and the cross reactivity itself in mAb, so clinical application of ELISA using mAb against MEPE has not been established. However, our in vitro study confirmed that the possible importance of the measurement of osteocyte-specific protein and showed the next target protein for development of clinically applicable plasma concentration measurement.